CGEN Compugen Ltd.

6.78
+0.18  (+3%)
Previous Close 6.6
Open 6.6
Price To Book 10.12
Market Cap 423,033,083
Shares 62,394,260
Volume 368,447
Short Ratio
Av. Daily Volume 258,108
Stock charts supplied by TradingView

NewsSee all news

  1. Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones

    HOLON, Israel, Jan. 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its

  2. Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

    HOLON, Israel, Jan. 8, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of Oliver Froescheis,

  3. Compugen Added to the NASDAQ Biotechnology Index

    HOLON, Israel, Dec. 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition

  4. Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors

    –Addition of Experienced Executive to Leadership Team– CAMBRIDGE, Mass. and MISSISSAUGA, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery

  5. Compugen Reports Third Quarter 2019 Results

    HOLON, Israel, Nov. 11, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy  company and a leader in predictive target discovery, today reported financial results for the third

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data due 2H 2020.
COM701
Solid tumors
Phase 1 trial initiated September 2018.
BAY 1905254
Solid tumors
Phase 1 trial to be initiated early 2020 with data due 2021.
COM902
Advanced cancer

Latest News

  1. Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones

    HOLON, Israel, Jan. 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its

  2. Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

    HOLON, Israel, Jan. 8, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of Oliver Froescheis,

  3. Compugen Added to the NASDAQ Biotechnology Index

    HOLON, Israel, Dec. 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition

  4. Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors

    –Addition of Experienced Executive to Leadership Team– CAMBRIDGE, Mass. and MISSISSAUGA, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery

  5. Compugen Reports Third Quarter 2019 Results

    HOLON, Israel, Nov. 11, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy  company and a leader in predictive target discovery, today reported financial results for the third

  6. Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

    HOLON, Israel, Nov. 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has

  7. Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

    HOLON, ISRAEL, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902

  8. Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

    HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing

  9. Compugen Announces FDA Clearance of IND Application for COM902

    HOLON, ISRAEL, Nov. 4, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug

  10. Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

    HOLON, Israel, Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced it will present three

  11. Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS

    HOLON, Israel, Sept. 19, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced progress in its ongoing Phase 1 clinical